UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide

NCT00574080 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

20

Enrollment

OTHER

Sponsor class

Stopped low accrual

Conditions

Multiple Myeloma

Interventions

DRUG: Interim/Maintenance Dexamethasone
DRUG: Induction/Consolidation Dexamethasone
DRUG: Induction/Consolidation Cisplatin
DRUG: Induction/Consolidation Adriamycin
DRUG: InductionConsolidation Cyclophosphamide
DRUG: Induction/Consolidation Etoposide
DRUG: Induction Pegfilgrastim
DRUG: Transplant 1 Dexamethasone
DRUG: Transplant 1 Cisplatin
DRUG: Transplant 1 Adriamycin
DRUG: Transplant 1 Cyclophosphamide
DRUG: Transplant 1 Etoposide
DRUG: Transplant 1 Melphalan
DRUG: Transplant 1 and 2 Pegfilgrastim
PROCEDURE: Autologous Peripheral Blood Stem Cell Transplant (ASCT)
DRUG: Transplant 2 Carmustine
DRUG: Transplant 2 Etoposide
DRUG: Transplant 2 Cytarabine
DRUG: Transplant 2 Melphalan
DRUG: Transplant 2 Dexamethasone

Sponsor

University of Arkansas